Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Viking Therapeutics Stock a Better Buy Than Eli Lilly and Novo Nordisk After the Latest Weight-Loss Drug News?

TheMotleyFool 
0 0 06.03.24
Is Viking Therapeutics Stock a Better Buy Than Eli Lilly and Novo Nordisk After the Latest Weight-Loss Drug News?: https://g.foolcdn.com/editorial/images/768024/scientists-smiling-and-shaking-hands.jpg
 

Just when the weight-loss drug market was heating up, the temperature rose even more. Eli Lilly (NYSE: LLY) is already giving Novo Nordisk (NYSE: NVO) a run for its money with the approval in the fourth quarter of 2023 of Zepbound. Now another rival could be on the way.

Viking Therapeutics (NASDAQ: VKTX) announced results last week from a phase 2 clinical study of VK2735 in helping patients lose weight. Its share price promptly skyrocketed more than 130%. Is Viking Therapeutics stock a better buy than Eli Lilly or Novo Nordisk after its latest weight-loss drug news?

Some Wall Street analysts project that the market for weight loss drugs could reach or even top $100 billion by 2030. This expectation has helped fuel massive gains for Lilly and Novo Nordisk. Both pharma stocks are up more than 250% over the last three years.

Continue reading


Source Fool.com

Viking Therapeutics Inc Stock

€57.42
1.480%
There is an upward development for Viking Therapeutics Inc compared to yesterday, with an increase of €0.84 (1.480%).

Show more
Like: 0
VKTX
Share

Comments

Not a member yet? Sign up for free!